Medication info
Mteranapin Tablets (Terbinafine Hydrochloride)

Mteranapin Tablets (Terbinafine Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
McNulty Pharmaceutical Co., Ltd.
Appearance
White to whitish round tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201603638 · Approved 2016.06.20 · Insurance code 641502210

Summary

Main use
Treatment of onychomycosis, cutaneous fungal infections (tinea pedis, tinea corporis, etc.), and tinea capitis
Who uses it
Adults · Children
Adult dosage
Administer terbinafine 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2 to 6 weeks Tinea corporis: 2 to 4 weeks Tinea cruris: 2 to 4 weeks 2) Onychomycosis Treatment is usually administered for 6 weeks to 3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow nail growth. 3. Patients with Renal Impairment In patients with creatinine clearance less than 50 mL/min, reduce the daily dose by 1/2.
Children's dosage
Administer to children 2 years of age and older. Administration is not recommended in children under 2 years of age because there is no experience with use in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the appropriate prescribed duration. 1) Body weight under 20 kg (under 5 years): Administer 62.5 mg once daily. Because experience with use is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. 2) Body weight 20 to 40 kg (5 to 12 years): Administer 125 mg once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Ingredients

Manufacturer
McNulty Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of onychomycosis, cutaneous fungal infections (tinea pedis, tinea corporis, etc.), and tinea capitis

  • Dermatophyte-related skin infections
  • athlete's foot
  • tinea corporis
  • tinea cruris
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used in adults for the treatment of dermatophyte infections such as athlete's foot, tinea corporis, tinea cruris, and onychomycosis, as well as tinea capitis in children.

Dosage and Administration

Adult dosage

Administer terbinafine 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2 to 6 weeks Tinea corporis: 2 to 4 weeks Tinea cruris: 2 to 4 weeks 2) Onychomycosis Treatment is usually administered for 6 weeks to 3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow nail growth. 3. Patients with Renal Impairment In patients with creatinine clearance less than 50 mL/min, reduce the daily dose by 1/2.

Children's dosage

Administer to children 2 years of age and older. Administration is not recommended in children under 2 years of age because there is no experience with use in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the appropriate prescribed duration. 1) Body weight under 20 kg (under 5 years): Administer 62.5 mg once daily. Because experience with use is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. 2) Body weight 20 to 40 kg (5 to 12 years): Administer 125 mg once daily. 3) Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Precautions

This medication is not recommended for patients with poor liver function. It is essential to check for liver disease before taking and to undergo regular liver function tests before and during treatment. If symptoms of liver dysfunction appear, discontinue use immediately and consult a physician. This drug should not be used in patients with certain blood disorders, severe kidney dysfunction, children under 2 years of age, and nursing women. Patients with genetic metabolic disorders such as lactose intolerance should also avoid this medication. Use caution in patients with compromised kidney function, elderly patients over 65, and underweight children. If severe skin rashes or allergic reactions occur, discontinue use immediately. This medication can cause various adverse reactions related to the liver, so frequent liver function tests and monitoring of symptoms are recommended from the start of treatment. Adverse effects can occur in various systems including blood, skin, muscles, digestive system, and nervous system, so if any unusual symptoms appear, notify a physician immediately. This medication may interact with other drugs, so if you are taking other medications, inform your physician or pharmacist, especially when using medications metabolized by the liver. Women who are pregnant or may become pregnant should use this medication with caution, and nursing mothers should discontinue breastfeeding while taking it. Administer this medication carefully to children and the elderly, as overdose may lead to symptoms such as headaches, nausea, and dizziness.

Side effects

Liver failure, hepatitis, biliary stasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, skin and mucous membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, psoriasiform rash, worsening of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distension, decreased appetite, dyspepsia, mild abdominal pain, diarrhea, abdominal discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, taste disturbance, dizziness, drowsiness, sensory disturbances, sensory loss, decreased attention span, insomnia, elevated BUN, polyuria, visual impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated serum total cholesterol, elevated triglycerides, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, vision loss, hearing loss, auditory impairment, vasculitis, permanent anosmia, hyposmia, drug rash accompanied by eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased blood creatine phosphokinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a well-closed container, away from air, and at a temperature between 1 and 30 degrees Celsius. Storing in this manner will keep the ingredients stable and safe for use.

Appearance and packaging

Appearance

White to whitish round tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.